Introduction
============

Nanotechnology is being explored with the goal of improving nanomedicine for human health.[@b1-ijn-8-4277],[@b2-ijn-8-4277] There is an interest in the synthesis of nanomaterials because they exhibit unique physical, chemical, optical, electrical, magnetic, mechanical, thermal, dielectric, and biological properties, different from those of bulk materials, due to their distinct size- and shape-dependent characteristics.[@b3-ijn-8-4277] Silver is a natural antimicrobial agent.[@b4-ijn-8-4277] Therefore, silver nanoparticles (AgNPs) exhibit great potential as novel antimicrobial agents. Besides their antimicrobial properties, AgNPs are also reported to exhibit anti-angiogenesis,[@b5-ijn-8-4277] anti-inflammatory,[@b6-ijn-8-4277] and anti-platelet[@b7-ijn-8-4277] activities. Hence, AgNPs have diverse medical applications.[@b8-ijn-8-4277]--[@b10-ijn-8-4277] Although there are reports on the antimicrobial activity of free AgNPs and in combination with antibiotics,[@b11-ijn-8-4277]--[@b16-ijn-8-4277] very few reports have examined the effect of AgNPs on antibiotics belonging to different classes.[@b17-ijn-8-4277]

AgNPs can be synthesized by chemical,[@b18-ijn-8-4277] physical,[@b19-ijn-8-4277],[@b20-ijn-8-4277] or biological routes involving plants[@b8-ijn-8-4277],[@b17-ijn-8-4277],[@b21-ijn-8-4277],[@b22-ijn-8-4277] or microorganisms.[@b23-ijn-8-4277]--[@b28-ijn-8-4277] Biological synthesis is preferred nowadays because these methods are safe, cheap, eco-friendly, and do not involve any toxic substrate or by-product.[@b29-ijn-8-4277] Unlike plants, microbial-mediated synthesis of nanoparticles is not affected by geographical and seasonal variations, avoiding inconsistent morphologies and properties. Reports are available on AgNP synthesis employing pathogenic and nonpathogenic bacterial cells and/or supernatant such as *Klebsiella pneumoniae*, *Enterobacter* spp., *Pseudomonas aeruginosa*, and *Bacillus* spp.[@b14-ijn-8-4277],[@b25-ijn-8-4277]--[@b28-ijn-8-4277] Microorganisms synthesize nanoparticles either intra- or extracellularly. Extracellular synthesis has advantages, since retrieval of nanoparticles is easy compared with intracellular synthesis where additional recovery steps are required.

*Acinetobacter* spp. is most commonly found in the environment including human skin microbiota[@b30-ijn-8-4277] and the mucus membrane of the upper respiratory tract.[@b31-ijn-8-4277] It is a versatile group of microbes with respect to nutrition, metabolism, and genetic organization.[@b32-ijn-8-4277]*Acinetobacter* spp. have been reported to exhibit metal resistance[@b33-ijn-8-4277] and plant growth-promoting properties such as phosphate and zinc solubilization,[@b34-ijn-8-4277] implying their ability to interact with metals rendering them nontoxic for their survival. So far there are only two preliminary reports which have included *Acinetobacter* spp. for synthesis of AgNPs; one being *A. schindleri* isolated from soil,[@b35-ijn-8-4277] and another is *A. calcoaceticus* W17.[@b36-ijn-8-4277] However, detailed reports on the synthesis of AgNPs by genus *Acinetobacter* are not known. In view of this background, we proposed that *Acinetobacter* isolated from wheat rhizosphere may produce novel and unique nanoparticles with respect to size, shape, and biological activities. We also investigated the effects of reaction parameters on the rate of synthesis and morphology of the AgNPs. Synergistic effects of these AgNPs on activity of different antibiotics have been evaluated against pathogenic Gram-negative and Gram-positive bacteria.

Material and methods
====================

Cultures
--------

Eighteen strains of *Acinetobacter* spp., isolated from the wheat rhizosphere (Pune, Maharashtra, India), were used to screen the synthesis of AgNPs.[@b34-ijn-8-4277] These were already identified by 16S rRNA sequencing (GenBank EU221346, EU221386, EU221389, EU921458--EU921472). The cultures were maintained on a Luria Bertani (HiMedia, Mumbai, India) agar plate/slant at 4°C and as glycerol stocks at −80°C. For inoculum preparation, a loopful of the culture was inoculated into 250 mL sterile Luria Bertani broth and incubated at 30°C/200 rpm for 24 hours. The cells were harvested by centrifugation at 6,000 rpm for 7 minutes at 4°C.

Standard cultures for antibacterial assays were procured from Microbial Type Culture Collection (MTCC), Chandigarh, India and National Collection of Industrial Microorganisms (NCIM), Pune, India. These include Gram-negative (*Enterobacter aerogenes* NCIM 2964, *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* NCIM 5029, *Shigella sonnie* MTCC 2957, *Salmonella typhimurium* NCIM 2509), and Gram-positive (*Staphylococcus aureus* MTCC 3160, *Streptococcus mutans* MTCC 497) bacterial pathogens. *Acinetobacter baumannii* AIIMS 7 (GenBank EU779829) isolated and identified in our laboratory has been used.[@b37-ijn-8-4277]

Synthesis of AgNPs and ultraviolet-visible (UV-Vis) spectra analysis
--------------------------------------------------------------------

For screening, the cells of *Acinetobacter* spp. (optical density \[OD\]~600~ ≈1 × 10^10^ CFU/mL) were suspended into sterile Milli-Q® water (pH 7) after repeated rinses to remove the traces of media and incubated at 30°C/200 rpm for 72 hours. Cell-free extract (CFE) used for synthesis was collected by passing the supernatant obtained after centrifugation through a 0.2 μm syringe filter (Pall Corporation, Port Washington, NY, USA). Three flasks, the first containing 1 mM AgNO~3~ (HiMedia) without CFE, the second containing only CFE, and the third containing CFE with 1 mM AgNO~3~, were incubated at 40°C in static conditions. Synthesis of AgNPs was visually observed for a color change over a period of 168 hours. Reduction of Ag^+^ ions was monitored by recording the UV-Vis spectrum between 300 and 800 nm at regular intervals up to 168 hours on SpectraMax M5 Multi-mode Microplate Reader (Molecular Devices LLC, Sunnyvale, CA, USA). The strain giving maximum absorbance was selected.

Characterization of AgNPs
-------------------------

After 168 hours of synthesis, the sample of AgNPs was centrifuged at 14,000 rpm for 30 minutes at room temperature. Repeated rinses were performed to remove impurities. The pellet of AgNPs was suspended in 1 mL sterile Milli-Q water. The X-ray diffraction (XRD) data of dried thin films of AgNPs on a glass slide was recorded by D8 Advanced Brucker X-ray diffractometer with a Cu Kα (1.5Å) source. A drop of AgNP sample was dried on a glass slide for analysis under a scanning electron microscope (SEM) (JSM-6360; JEOL, Tokyo, Japan) at 20 kV accelerating voltage. Samples for transmission electron microscopy (TEM) and high-resolution TEM (HR-TEM) were prepared by drop-coating the AgNPs solution on a carbon-coated copper grid and drying under infrared radiation. The analyses were performed on FEI Tecnai G^2^ 12 BioTwin (FEI Company, Eindhoven, the Netherlands) TEM and JEM-2100 (JEOL) HR-TEM. The presence of elemental silver was confirmed through energy-dispersive spectroscopy (EDS) (JED-2300; JEOL), equipment included with the HR-TEM. The particle size of a 3 mL sample was estimated using a dynamic light scattering instrument (Zetasizer Nano-2590; Malvern Instruments Ltd, Worcestershire, UK) in a polystyrene cuvette.

Effect of reaction parameters on morphology of AgNPs
----------------------------------------------------

To obtain the optimized reaction parameters giving maximum synthesis of AgNPs, firstly, AgNO~3~ ranging from 0.5 to 5 mM (final concentration) was added to the CFE and incubated at 40°C for up to 168 hours. After this, the optimum concentration of AgNO~3~ was added to the CFE and incubated for 168 hours at 4°C--80°C for temperature optimization. Besides UV-Vis spectra, TEM analyses were carried out to study morphology with varying salt concentrations and reaction temperatures.

Antibacterial assay
-------------------

Fourteen antibiotics, namely, amikacin, gentamicin, kanamycin, amoxicillin, ampicillin, ceftriaxone, vancomycin, ciprofloxacin, doxycycline, tetracycline, chloramphenicol (HiMedia, Mumbai, India), trimethoprim (Sigma-Aldrich, St. Louis, MO, USA), ceftazidime (GlaxoSmithKline Pharmaceutical Limited, Nashik, India), and penicillin (Alembic Pharmaceutical Limited, Vadodara, India), were used for antibacterial assay. The disc-diffusion method was used to assay the antibacterial activity of the AgNPs, antibiotics, and combination of both against pathogenic bacteria on Mueller-Hinton (MH) (HiMedia) agar plates. In brief, a single colony of each test strain was grown overnight in MH broth on a rotary shaker (150 rpm) at 37°C. The OD was adjusted to 0.5 McFarland (≈1 × 10^8^ CFU/mL), and cultures were applied to the plates along with discs containing AgNPs (1--1,024 μg/disc) and antibiotics (30 μg/disc). To determine the synergistic effects, discs with 30 μg of antibiotic were further impregnated with 5 μL of freshly prepared AgNPs (15 μg/disc). After incubation at 37°C for 20 hours, the zones of inhibition were measured. The assays were performed in duplicate.

The minimum inhibitory concentration (MIC) was determined by broth microdilution method given by the Clinical Laboratory Standards Institute (CLSI) using 96-well microtiter plates. Two-fold serial dilutions of AgNPs and antibiotics were made using MH broth. Each plate included growth and sterility control wells. To each well, 5 μL inoculum (≈5 × 10^5^ CFU/mL) was added. To evaluate the effect of AgNPs on MICs of antibiotics, a sub-inhibitory concentration of AgNPs was added to the wells containing different concentrations of antibiotics so that the final concentration of AgNPs in each well was 15 μg. The microtiter plates were incubated at 37°C for 20 hours, and results were recorded. The lowest concentration completely inhibiting the growth as detected by the unaided eye was reported as the MIC. The assays were performed in duplicate. MIC breakpoints of the CLSI 2007[@b38-ijn-8-4277] guidelines were used to define a resistant or susceptible strain.

From the above assay, a 5 μL aliquot was taken from the wells showing no visual growth after incubation and spotted onto MH agar plates. The lowest concentration showing no colony on the MH agar after 20 hours of incubation at 37°C was recorded as the minimum bactericidal concentration. These were performed in duplicate.

Results and discussion
======================

Synthesis of AgNPs
------------------

A study on the biosynthesis of AgNPs by CFE of 18 strains of *Acinetobacter* spp. isolated from the wheat rhizosphere was carried out. Only *A. calcoaceticus* LRVP54 gave a positive result for synthesis of AgNPs within 24 hours. This indicates that although these bacteria possess plant growth-promoting properties,[@b34-ijn-8-4277] only one has the ability to synthesize AgNPs. Visual observation of CFE incubated with AgNO~3~ showed a color change from colorless to reddish brown, clearly indicating the formation of AgNPs ([Figure 1A](#f1-ijn-8-4277){ref-type="fig"}). In the UV-Vis spectrum, a single, strong, and broad peak was observed at 440 nm, confirming the synthesis of AgNPs using CFE ([Figure 1A](#f1-ijn-8-4277){ref-type="fig"}). In metal nanoparticles such as silver, the electrons move freely due to the close proximity of the conduction and valence bands.[@b39-ijn-8-4277] The collective oscillation of electrons of AgNPs in resonance with the light wave gives rise to a unique surface plasmon resonance (SPR) absorption band which is also the origin of the observed color.[@b40-ijn-8-4277],[@b41-ijn-8-4277] A peak located between 410 and 440 nm has been observed for AgNPs and is well documented for metal nanoparticles with sizes from 2 to 100 nm.[@b41-ijn-8-4277] According to Mie's theory, only a single SPR band is expected in the absorption spectra of spherical metal nanoparticles, whereas anisotropic particles could give rise to two or more SPR bands, depending on the shape of the particles.[@b42-ijn-8-4277],[@b43-ijn-8-4277] In our case, a single SPR peak was observed, which suggests that our AgNPs were spherical in shape and is consistent with the TEM observations. With the progress of reaction time, more and more Ag^+^ were reduced to Ag^0^, resulting in an increased concentration of AgNPs as indicated by increased OD of the SPR band (λ~max~ =440 nm) with time. The major reason for SPR broadening is electron surface scattering, which may be enhanced for small aggregates.[@b40-ijn-8-4277] AgNPs formed in this process were stable, and the absorption spectra found to be unaltered even after 6 months at room temperature.

The mechanism behind biosynthesis of AgNPs using microorganisms is still not clear. Peptides, proteins, and DNA have been suggested to act as templates for reducing metal ions to form nanoparticles.[@b23-ijn-8-4277],[@b44-ijn-8-4277]--[@b47-ijn-8-4277] There are reports suggesting the involvement of enzymes such as nitrate reductase and phyochelatin synthase as reducing agents for AgNPs synthesis in bacteria and fungi.[@b23-ijn-8-4277],[@b46-ijn-8-4277],[@b47-ijn-8-4277] We observed that the nanoparticles were embedded in an organic matrix. It seems that these biomolecules are secreted by the cells in the CFE, which may act as reducing and stabilizing agents.

Characterization of AgNPs
-------------------------

The exact nature of the AgNPs can be deduced from the XRD spectrum of the sample. The XRD pattern ([Figure 1B](#f1-ijn-8-4277){ref-type="fig"}) showed four peaks at 2θ values of 38.1°, 44.3°, 64.4°, and 77.2°, corresponding to (111), (200), (220), and (311) respectively, in the whole spectrum of 2θ values ranging from 20° to 80°. A comparison of our XRD spectrum with the Standard (JCPDS file no 04-0783) confirmed the formation of crystalline AgNPs, in accordance with the study of Kalimuthu et al.[@b27-ijn-8-4277] SEM of the sample showed the formation of nanoparticles in dispersed and aggregated forms which were confirmed to be of silver by EDS ([Figure 2A](#f2-ijn-8-4277){ref-type="fig"} and [B](#f2-ijn-8-4277){ref-type="fig"}). EDS analysis showed a peak at 3 keV, which is typical for the absorption of metallic silver nanocrystallites due to SPR, thereby confirming the formation of AgNPs.[@b14-ijn-8-4277] Additional peaks for copper were observed due to the copper grid used for EDS analysis. TEM analyses revealed the synthesis of polydisperse AgNPs of 10--60 nm size from 1 mM AgNO~3~ after 168 hours. Aggregates and dispersed nanoparticles were found to be embedded in an organic matrix ([Figure 2C](#f2-ijn-8-4277){ref-type="fig"}). Namasivayam et al employed a similar method for biosynthesis of AgNPs using CFE of *Lactobacillus acidophilus* 01 where production of spherical AgNPs of 45--60 nm was reported.[@b24-ijn-8-4277] Dynamic light scattering data ([Figure 2C](#f2-ijn-8-4277){ref-type="fig"}) showed that the majority of AgNPs synthesized with 1 mM AgNO~3~ were in the range of 15--60 nm, along with some aggregates, which is well in agreement with SEM and TEM results. Also HR-TEM imaging distinctly showed the lattice fringes wherein *d* (the distance between two lattice fringes) was 0.23 nm ([Figure 2D](#f2-ijn-8-4277){ref-type="fig"}), typically observed for the crystalline structure of the AgNPs.[@b22-ijn-8-4277]

Effect of reaction parameters on morphology of AgNPs
----------------------------------------------------

Optimization studies revealed the significant effects of concentration of metal salt and reaction temperature on the rate of bioreduction of silver ions to AgNPs. Morphological changes during variation of parameters were observed under TEM. At a fixed temperature of 40°C, variation in reaction kinetics was observed for the synthesis of nanoparticles by varying the AgNO~3~ concentration ([Figure 3A](#f3-ijn-8-4277){ref-type="fig"}). Maximum synthesis of nanoparticles occurred at 0.7 mM AgNO~3~ in the reaction mixture, followed by 0.5 mM AgNO~3~. Highest concentration of 5 mM AgNO~3~ showed the least bioreduction of silver ions to nanoparticles. This can be explained on the basis of enzyme-substrate kinetics; ie, the active site in the key biomolecule responsible for reduction is already saturated with the silver ions, and no site is available for excess ions to get reduced, hence there is no further increase in synthesis of AgNPs despite the addition of more salt. As compared with the UV-Vis spectrum obtained for 1 mM AgNO~3~ after 168 hours, a blue shift from 440 to 430 nm was observed at 0.7 mM ([Figure 3B](#f3-ijn-8-4277){ref-type="fig"}), which could be due to the variation in morphology of nanoparticles synthesized with different salt concentrations. At the optimized AgNO~3~ concentration of 0.7 mM, rate of synthesis was found to increase with an increase in reaction temperature up to 70°C, which showed maximum synthesis ([Figure 4A](#f4-ijn-8-4277){ref-type="fig"}), after which a decline in the synthesis was observed. A further blue shift in the SPR peak to 420 nm was observed at 70°C after 168 hours of incubation ([Figure 4B](#f4-ijn-8-4277){ref-type="fig"}). It has been reported that small and homogeneous distribution of AgNPs causes the blue shift in UV-Vis spectrum,[@b48-ijn-8-4277] parallel with our results as confirmed by UV-Vis spectrum and TEM images.

TEM analysis showed the formation of monodisperse spherical AgNPs of 8--12 nm size at 70°C with 0.7 mM AgNO~3~ ([Figure 5](#f5-ijn-8-4277){ref-type="fig"}). Deviations from these optimized parameters resulted in an increase in size and polydispersity of AgNPs as observed under TEM. Despite a large number of reports on the synthesis of AgNPs using bacteria, only few reports are available on the optimization. One such study was reported by Gurunathan et al, for *E. coli*-mediated AgNP synthesis, where 5 mM AgNO~3~, 60°C temperature, and pH 10 were reported to provide optimal conditions for the maximal synthesis of small sized nanoparticles.[@b49-ijn-8-4277] In the present study, the enhanced rate of synthesis of AgNPs at optimized conditions might be the direct result of the effect of substrate (silver ions) and temperature on a key biomolecule responsible for reduction present in the CFE of *A. calcoaceticus* LRVP54. It has been suggested that increase in reaction rate causes most silver ions to be consumed in the formation of nuclei and thus stops the secondary reduction process on the surface of the preformed nuclei, leading to the formation of smaller size particles.[@b49-ijn-8-4277] However, to have completely monodisperse nanoparticles through biological systems is still a big challenge.

Antibacterial activity of AgNPs
-------------------------------

Silver and its compounds are known for their antimicrobial properties and for the treatment of burns and chronic wounds.[@b50-ijn-8-4277],[@b51-ijn-8-4277] High surface area to volume ratio cause high bactericidal activity of AgNPs compared with bulk silver metal.[@b52-ijn-8-4277],[@b53-ijn-8-4277] Here, individual and combined effects of AgNPs with 14 antibiotics belonging to seven classes were investigated against seven pathogenic bacteria using the disc- diffusion method. AgNPs exhibited antibacterial activity against *P. aeruginosa* and *A. baumannii* compared with *S. aureus* and *S. mutans* as observed by the zone of inhibition ([Table S1](#SD1-ijn-8-4277){ref-type="supplementary-material"}). Similar results were obtained by Fayaz et al.[@b16-ijn-8-4277] The reason for this is the structural difference in cell wall composition of Gram-positive and Gram-negative bacteria. Gram-positive bacteria possess a thick layer of peptidoglycan (20--80 nm), making it difficult for AgNPs to penetrate.[@b16-ijn-8-4277] Wide variation has been found in the activities of antibiotics in the presence and absence of AgNPs, which is interpreted in terms of an increase in the area of zones of inhibition ([Table 1](#t1-ijn-8-4277){ref-type="table"}). Aminoglycosides showed a minute increase in the range 0.0--0.8 fold, with the exception of gentamicin against *A. baumannii* and kanamycin against *P. aeruginosa*, where a 1.8-fold increase was seen. Considerable enhancement in antibacterial activity was observed for amoxicillin in the presence of AgNPs against *P. aeruginosa*, where a 1.8-fold increase was observed. For penicillin, in the presence of AgNPs, a 3.0-fold increase against *S. mutans* was observed. Vancomycin was found to have the highest overall synergistic activity in combination with AgNPs compared with all other antibiotics. For *E. aerogenes*, a 3.8-fold increase in inhibition zone was observed with the combination of vancomycin and AgNPs. In a similar study, Ghosh et al reported the synergy using a 30 μg/disc of AgNPs synthesized by *Dioscorea bulbifera* tuber extract and 500 μg of each antibiotic.[@b17-ijn-8-4277] Our findings are comparable to their results even though we only used 30 μg/disc of antibiotics and 15 μg/disc of AgNPs.

The broth dilution assay was performed to determine the MIC. For AgNPs, MIC was in the range of 150--600 mg/L against Gram-negative bacteria, while for *S. aureus* and *S. mutans*, it was \>1,000 mg/L. Therefore, to evaluate the synergistic effects of AgNPs on the respective MICs of antibiotics, a sub-inhibitory concentration of 75 mg/L AgNPs was added to each well (15 μg/well). MIC breakpoints of the CLSI guidelines[@b38-ijn-8-4277] were used for comparison of the obtained results ([Table 2](#t2-ijn-8-4277){ref-type="table"}). MIC breakpoints are provided to define the resistance and susceptibility of pathogenic microorganisms depending on the extent of their antibiotic resistance. Interpretation of the antimicrobial results as per these guidelines will provide a greater understanding of the efficacy of AgNPs and their synergistic effects on antibiotics against pathogenic microorganisms. *E. coli* ATCC 25922, a control strain, was included in the study to check the accuracy of determined MICs. Out of seven bacteria, six exhibited resistance to one or more antibiotics belonging to the β-lactam class ([Table 2](#t2-ijn-8-4277){ref-type="table"}). With the addition of AgNPs, only Gram-negative bacteria were found to have a MIC in the susceptible range. Although a decrease in MIC was observed, *S. aureus* and *S. mutans* still exhibited resistance towards β-lactam antibiotics. Significant synergistic effects of AgNPs were observed against *A. baumannii*, which showed resistance to seven of the ten antibiotics. On exposure to AgNPs in combination with the antibiotics, the MICs were reduced significantly, and the bacteria were found to be susceptible to all of the antibiotics tested except cephalosporins, where no change was observed. Although Gram-positive bacteria showed resistance towards vancomycin, addition of AgNPs not only reduced the MIC but also made *S. mutans* susceptible to the antibiotic treatment. All pathogens were already susceptible to the tetracycline class of antibiotics; therefore, treatment with AgNPs was unnecessary, although a decrease in MICs could be observed. The corresponding minimum bactericidal concentrations of these bacteria were also reduced on addition of AgNPs in combination with antibiotics ([Table S2](#SD2-ijn-8-4277){ref-type="supplementary-material"}). It is important to note that although there are large numbers of reports on MICs of AgNPs against bacterial pathogens,[@b54-ijn-8-4277]--[@b56-ijn-8-4277] no study has been done to evaluate the synergistic potential of AgNPs with respect to the known CLSI standards. However, in this study, we not only showed the synergistic effects of AgNPs on the activity of antibiotics, but also determined its significance using MIC breakpoints given in the CLSI guidelines. This shows that the administration of a small amount of AgNPs in combination with antibiotics can reduce the required dose of antibiotics by up to a 1000-fold to achieve the same effect besides combating the problem of multidrug resistance among pathogenic bacteria.

Antibacterial mechanisms of antibiotics are well-known.[@b57-ijn-8-4277] Multiple mechanisms have been suggested to explain the antibacterial activity of AgNPs, such as release of silver ions from AgNPs,[@b16-ijn-8-4277] generation of reactive oxygen species, disruption of cellular morphology, inactivation of vital enzymes, DNA condensation,[@b11-ijn-8-4277] and loss of DNA replication.[@b58-ijn-8-4277] Emerging resistance among bacteria renders the available antibiotics inefficient. Synergistic action of AgNPs and antibiotics resulted in enhanced antibacterial effect. Moreover, simultaneous action of antibiotics and AgNPs will make it difficult for pathogenic bacteria to develop resistance, and hence, this combinational therapy can be further studied to develop new formulations of AgNPs in conjunction with antibiotics.

Conclusion
==========

This is the first report on biological synthesis of AgNPs using *A. calcoaceticus* LRVP54, an environmental isolate from the wheat rhizosphere. The optimization of reaction parameters resulted in monodisperse spherical AgNPs of size 8--12 nm. The efficiency of AgNPs to increase the susceptibility of drug-resistant bacteria measured as per MIC breakpoints of the CLSI standard we report here for the first time. Further studies on the mechanistic aspect of biosynthesis of AgNPs, and their bactericidal activity are currently under investigation.

Supplementary tables
====================

###### 

Zone of inhibition obtained with different concentrations of AgNPs against pathogenic microorganisms

  AgNP (μg/disc)   Zone of inhibition (mm)                                 
  ---------------- ------------------------- ---- ---- ---- ---- ---- ---- ----
  1,024            15                        12   14   17   14   13   7    12
  512              14                        11   12   15   13   11   NI   10
  256              12                        10   10   14   12   8    NI   9
  128              11                        9    8    12   10   NI   NI   8
  64               10                        8    NI   11   9    NI   NI   7
  32               7                         NI   NI   10   8    NI   NI   NI
  16               NI                        NI   NI   8    7    NI   NI   NI

**Note:** All experiments were repeated twice, and standard deviations were insignificant.

**Abbreviations:** AgNP, silver nanoparticle; NI, no inhibition.

###### 

MBC of antibiotics (μg/mL) against pathogenic microorganisms in the presence and absence of AgNPs

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibiotics           *Escherichia coli*\   *Acinetobacter baumannii*\   *Enterobacter aerogenes*\   *Pseudomonas aeruginosa*\   *Shigella sonnie*\   *Salmonella typhimurium*\   *Staphylococcus aureus*\   *Streptococcus mutans*\                                                                  
                        ATCC\                 AIIMS\                       NCIM\                       NCIM\                       MTCC\                NCIM\                       MTCC\                      MTCC\                                                                                    
                        25922                 7                            2964                        5029                        2957                 2501                        3160                       497                                                                                      
  --------------------- --------------------- ---------------------------- --------------------------- --------------------------- -------------------- --------------------------- -------------------------- ------------------------- --------- --------- ------ --------- --------- --------- ----- ---------
  **Aminoglycosides**                                                                                                                                                                                                                                                                                   

  Amikacin              1                     \<0.015                      128                         2                           1                    \<0.015                     0.5                        \<0.015                   0.5       \<0.015   1      \<0.015   1         \<0.015   --    --

  Gentamicin            0.25                  \<0.015                      512                         2                           0.25                 \<0.015                     0.125                      \<0.015                   0.06      \<0.015   0.5    \<0.015   0.125     0.125     --    --

  Kanamycin             1                     0.125                        --                          --                          256                  0.125                       512                        2                         0.5       \<0.015   2      \<0.015   1         0.125     --    --

  **β-Iactams**                                                                                                                                                                                                                                                                                         

  Amoxicillin           32                    0.125                        \>4,096                     64                          1,024                2                           --                         --                        2,048     32        --     --        2,048     128       --    --

  Ampicillin            16                    0.125                        \>4,096                     64                          128                  0.125                       --                         --                        256       64        32     \<0.015   512       64        64    32

  Penicillin            --                    --                           --                          --                          --                   --                          --                         --                        --        --        --     --        4,096     0.125     128   2

  **Cephalosporins**                                                                                                                                                                                                                                                                                    

  Ceftazidime           0.125                 0.03                         512                         512                         1                    \<0.015                     0.5                        \<0.015                   1         0.125     2      \<0.015   0.5       0.06      16    \<0.015

  Ceftriaxone           0.5                   \<0.015                      2,048                       2,048                       \<0.015              \<0.015                     32                         0.125                     0.5       0.125     16     \<0.015   1         0.25      2     \<0.015

  **Glycopeptides**                                                                                                                                                                                                                                                                                     

  Vancomycin            --                    --                           --                          --                          --                   --                          --                         --                        --        --        --     --        512       64        4     0.125

  **Quinolones**                                                                                                                                                                                                                                                                                        

  Ciprofloxacin         \<0.015               \<0.015                      16                          4                           \<0.015              \<0.015                     0.06                       \<0.015                   \<0.015   \<0.015   0.25   0.25      \<0.015   \<0.015   --    --

  **Tetracyclines**                                                                                                                                                                                                                                                                                     

  Doxycycline           8                     \<0.015                      64                          0.5                         32                   \<0.015                     --                         --                        64        \<0.015   64     \<0.015   32        4         --    --

  Tertacycline          8                     \<0.015                      64                          0.5                         32                   \<0.015                     --                         --                        128       0.06      128    0.5       16        2         1     \<0.015

  **Others**                                                                                                                                                                                                                                                                                            

  Chloramphenicol       32                    0.06                         --                          --                          64                   0.125                       --                         --                        128       \<0.015   128    \<0.015   4,096     1024      4     0.5

  Trimethoprim          0.25                  0.25                         64                          0.5                         0.125                \<0.015                     --                         --                        4,096     4         16     \<0.015   2         0.5       4     \<0.015
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** All experiments were repeated twice, and the higher of the two values was recorded. Columns A and B represent the MBC values of antibiotics and antibiotics in presence of AgNPs, respectively, for each pathogen.

**Abbreviations:** MBC, minimum bactericidal concentration; AgNP, silver nanoparticle.
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![Synthesis of AgNPs by CFE of *Acinetobacter calcoaceticus*. (**A**) UV-Vis spectra of AgNPs at different time-points with 1 mM AgNO~3~ at 40°C. Inset: Color change in CFE after addition of 1 mM AgNO~3~; (**B**) X-ray diffraction of AgNPs.\
**Abbreviations:** AgNP, silver nanoparticle; CFE, cell-free extract; UV-Vis, ultraviolet and visible absorption; AgNO~3~, silver nitrate; au, arbitrary units; h, hours.](ijn-8-4277Fig1){#f1-ijn-8-4277}

![Characterization of AgNPs synthesized with 1 mM AgNO~3~ at 40°C. (**A**) scanning electron microscopy image; (**B**) energy dispersive spectroscopy spectrum; (**C**) TEM image. Inset: Particle size distribution by dynamic light scattering; (**D**) HR-TEM image of AgNPs (*d* =0.23 nm).\
**Abbreviations:** AgNP, silver nanoparticle; AgNO~3~, silver nitrate; TEM, transmission electron microscopy; HR-TEM, high-resolution transmission electron microscopy.](ijn-8-4277Fig2){#f2-ijn-8-4277}

![Optimization of AgNO~3~ concentration for AgNP synthesis. (**A**) Time course of AgNP synthesis at 40°C using different concentrations of AgNO~3~; (**B**) UV-Vis spectra of AgNP synthesis at 40°C after 168 hours obtained with different concentrations of AgNO~3~.\
**Abbreviations:** AgNO~3~, silver nitrate; AgNP, silver nanoparticle; UV-Vis, ultraviolet and visible absorption spectroscopy; au, arbitrary units; h, hours.](ijn-8-4277Fig3){#f3-ijn-8-4277}

![Optimization of reaction temperature for AgNP synthesis. (**A**) Time course of AgNP synthesis with 0.7 mM AgNO~3~ at different reaction temperatures; (**B**) UV-Vis spectrum for AgNP synthesis with 0.7 mM AgNO~3~ after 168 hours at different reaction temperatures.\
**Abbreviations:** AgNP, silver nanoparticle; AgNO~3~, silver nitrate; UV-Vis, ultraviolet and visible absorption spectroscopy; au, arbitrary units; h, hours.](ijn-8-4277Fig4){#f4-ijn-8-4277}

![Morphology of AgNPs synthesized at varying reaction parameters. Upper panel shows the TEM images for AgNPs synthesized at 40°C with (**A**) 0.7 mM, (**B**) 2 mM, and (**C**) 4 mM silver salt after 168 hours. Lower panel shows the TEM images for AgNP biosynthesis with 0.7 mM AgNO~3~ at (**D**) 60°C, (**E**) 70°C, and (**F**) 80°C after 168 hours.\
**Abbreviations:** AgNP, silver nanoparticle; AgNO~3~, silver nitrate; TEM, transmission electron microscopy; CFE, cell-free extract, conc, concentration; temp, temperature; h, hours.](ijn-8-4277Fig5){#f5-ijn-8-4277}

###### 

Zone of inhibition (mm) of different antibiotics against pathogenic microorganisms in the presence and absence of AgNPs

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibiotic            *Escherichia coli*\   *Acinetobacter baumannii*\   *Enterobacter aerogenes*\   *Pseudomonas aeruginosa*\   *Shigella sonnie*\   *Salmonella typhimurium*\   *Staphylococcus aureus*\   *Streptococcus mutans*\                                                                                                       
                        ATCC 25922            AIIMS 7                      NCIM 2964                   NCIM 5029                   MTCC 2957            NCIM 2501                   MTCC 3160                  MTCC 497                                                                                                                      
  --------------------- --------------------- ---------------------------- --------------------------- --------------------------- -------------------- --------------------------- -------------------------- ------------------------- ----- ------ ------ ----- ------ ------ ----- ------ ------ ----- ------ ------ ----- ------ ------ -----
  **Aminoglycosides**                                                                                                                                                                                                                                                                                                                        

  Amikacin              23.0                  25.0                         0.2                         6.0                         8.0                  0.8                         23.0                       23.0                      0.0   26.0   27.0   0.1   24.0   25.0   0.1   15.0   17.0   0.3   20.0   21.0   0.1   24.0   26.0   0.2

  Gentamicin            28.0                  30.0                         0.1                         6.0                         10.0                 1.8                         23.0                       25.0                      0.2   28.0   30.0   0.1   20.0   23.0   0.3   20.0   20.0   0.0   20.0   20.0   0.0   25.0   25.0   0.0

  Kanamycin             22.0                  22.0                         0.0                         6.0                         6.0                  0.0                         18.0                       20.0                      0.2   6.0    10.0   1.8   20.0   22.0   0.2   19.0   20.0   0.1   19.0   20.0   0.1   14.0   18.0   0.6

  **β-Iactams**                                                                                                                                                                                                                                                                                                                              

  Amoxicillin           14.0                  14.0                         0.0                         6.0                         6.0                  0.0                         14.0                       17.0                      0.5   6.0    10.0   1.8   6.0    8.0    0.8   23.0   23.0   0.0   6.0    6.0    0.0   10.0   12.0   0.4

  Ampicillin            18.0                  20.0                         0.2                         6.0                         8.0                  0.8                         16.0                       19.0                      0.4   6.0    7.0    0.4   8.0    10.0   0.6   25.0   25.0   0.0   9.0    13.0   1.1   12.0   13.0   0.2

  Penicillin            15.0                  16.0                         0.1                         6.0                         6.0                  0.0                         20.0                       22.0                      0.2   6.0    7.0    0.4   10.0   10.0   0.0   23.0   25.0   0.2   6.0    6.0    0.0   6.0    12.0   3.0

  **Cephalosporins**                                                                                                                                                                                                                                                                                                                         

  Ceftazidime           28.0                  28.0                         0.0                         6.0                         6.0                  0.0                         30.0                       30.0                      0.0   29.0   31.0   0.1   25.0   25.0   0.0   32.0   33.0   0.1   23.0   25.0   0.2   11.0   13.0   0.4

  Ceftriaxone           27.0                  30.0                         0.2                         6.0                         6.0                  0.0                         34.0                       35.0                      0.1   23.0   23.0   0.0   20.0   25.0   0.6   30.0   32.0   0.1   20.0   25.0   0.6   14.0   14.0   0.0

  **Glycopeptides**                                                                                                                                                                                                                                                                                                                          

  Vancomycin            7.0                   9.0                          0.6                         7.0                         10.0                 1.0                         11.0                       24.0                      3.8   6.0    8.0    0.8   9.0    10.0   0.2   10.0   12.0   0.4   6.0    8.0    0.8   16.0   16.0   0.0

  **Quinolones**                                                                                                                                                                                                                                                                                                                             

  Ciprofloxacin         35.0                  36.0                         0.1                         18.0                        19.0                 0.1                         30.0                       32.0                      0.1   35.0   35.0   0.0   33.0   35.0   0.1   25.0   26.0   0.1   27.0   28.0   0.1   25.0   27.0   0.2

  **Tetracyclines**                                                                                                                                                                                                                                                                                                                          

  Doxycycline           25.0                  2.0                          0.0                         20.0                        23.0                 0.3                         25.0                       27.0                      0.2   8.0    12.0   1.2   19.0   20.0   0.1   22.0   24.0   0.2   16.0   19.0   0.4   24.0   29.0   0.5

  Tetracycline          28.0                  30.0                         0.1                         20.0                        20.0                 0.0                         30.0                       30.0                      0.0   15.0   18.0   0.4   27.0   28.0   0.1   24.0   24.0   0.0   21.0   23.0   0.2   21.0   21.0   0.0

  **Others**                                                                                                                                                                                                                                                                                                                                 

  Chloramphenicol       27.0                  30.0                         0.2                         14.0                        15.0                 0.1                         32.0                       34.0                      0.1   11.0   16.0   1.1   30.0   23.0   0.1   28.0   28.0   0.0   6.0    6.0    0.0   22.0   22.0   0.0

  Trimethoprim          26.0                  28.0                         0.2                         7.0                         9.0                  0.6                         30.0                       32.0                      0.1   6.0    9.0    1.2   30.0   30.0   0.0   21.0   21.0   0.0   25.0   26.0   0.1   6.0    6.0    0.0
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Increase (C) was calculated using the formula B^2^−A^2^/A^2^, where A and B are the zone of inhibition (mm) obtained for antibiotic alone and antibiotic in combination with AgNPs, respectively. In case of no zone of inhibition, diameter of the disc (6 mm) was taken for the calculation. All experiments were repeated twice, and standard deviations were negligible.

**Abbreviation:** AgNPs, silver nanoparticles.

###### 

MIC of antibiotics (μg/mL) against pathogenic microorganisms in the presence and absence of AgNPs

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibiotic            *Escherichia coli*\   *Acinetobacter baumannii*\   *Enterobacter aerogenes*\   *Pseudomonas aeruginosa*\   *Shigella sonnie*\   *Salmonella typhimurium*\   *Staphylococcus aureus*\   *Streptococcus mutans*\                                                                       
                        ATCC 25922            AIIMS 7                      NCIM 2964                   NCIM 5029                   MTCC 2957            NCIM 2501                   MTCC 3160                  MTCC 497                                                                                      
  --------------------- --------------------- ---------------------------- --------------------------- --------------------------- -------------------- --------------------------- -------------------------- ------------------------- --------- --------- --------- --------- --------- --------- ------- ---------
  **Aminoglycosides**                                                                                                                                                                                                                                                                                        

  Amikacin              1                     \<0.015                      128\*                       2                           1                    \<0.015                     0.5                        \<0.015                   0.5\*     \<0.015   1\*       \<0.015   1         \<0.015   --      --

  Gentamicin            0.25                  \<0.015                      256\*                       2                           0.25                 \<0.015                     0.125                      \<0.015                   0.06\*    \<0.015   0.125\*   \<0.015   0.125     \<0.015   --      --

  Kanamycin             1                     \<0.015                      --                          --                          64\*                 0.125                       512\*                      2                         0.5\*     \<0.015   0.5\*     \<0.015   1         \<0.015   --      --

  **β-Iactams**                                                                                                                                                                                                                                                                                              

  Amoxicillin           8                     0.125                        \>4096\*                    2                           1024\*               2                           --                         --                        2048\*    2         --        --        2048\*    16\*      --      --

  Ampicillin            8                     0.125                        \>4096\*                    2                           128\*                0.125                       --                         --                        256\*     2         4         \<0.015   128\*     8\*       64\*    2\*

  Penicillin            --                    --                           --                          --                          --                   --                          --                         --                        --        --        --        --        512\*     \<0.015   128\*   2\*

  **Cephalosporins**                                                                                                                                                                                                                                                                                         

  Ceftazidime           0.125                 0.03                         512\*                       512\*                       \<0.015              \<0.015                     0.5                        \<0.015                   1         0.125     0.03      \<0.015   0.06      0.06      16\*    \<0.015

  Ceftriaxone           0.06                  \<0.015                      2048\*                      2048\*                      \<0.015              \<0.015                     16                         0.125                     0.5       0.125     2         \<0.015   0.125     0.06      2       \<0.015

  **Glycopeptides**                                                                                                                                                                                                                                                                                          

  Vancomycin            --                    --                           --                          --                          --                   --                          --                         --                        --        --        --        --        512\*     64\*      4\*     0.125

  **Quinolones**                                                                                                                                                                                                                                                                                             

  Ciprofloxacin         \<0.015               \<0.015                      16\*                        0.125                       \<0.015              \<0.015                     0.03                       \<0.015                   \<0.015   \<0.015   0.06      \<0.015   \<0.015   \<0.015   --      --

  **Tetracyclines**                                                                                                                                                                                                                                                                                          

  Doxycycline           0.5                   \<0.015                      0.5                         \<0.015                     0.5                  \<0.015                     --                         --                        1         \<0.015   2         \<0.015   4         0.5       --      --

  Tetracycline          0.5                   \<0.015                      4                           \<0.015                     0.25                 \<0.015                     --                         --                        2         \<0.015   4         \<0.015   2         0.25      1       \<0.015

  **Others**                                                                                                                                                                                                                                                                                                 

  Chloramphenicol       2                     0.06                         --                          --                          1                    \<0.015                     --                         --                        2         \<0.015   2         \<0.015   512\*     128\*     2       \<0.015

  Trimethoprim          0.125                 \<0.015                      4\*\*                       \<0.015                     0.125                \<0.015                     --                         --                        128\*     2         0.125     \<0.015   0.25      0.06      2       \<0.015
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** MIC breakpoints of CLSI 2007 are used to define resistance (\*), intermediate (\*\*), and susceptibility of pathogens against 14 antibiotics. MIC breakpoint not provided in CLSI is represented by an empty cell (--). All experiments were repeated twice, and the higher of the two values was recorded. Columns A and B represent the MIC values of antibiotics and antibiotics in presence of AgNPs, respectively for each pathogen. *E coli* ATCC 25922 is a control strain for antibacterial susceptibility testing as per CLSI standards.

**Abbreviations:** MIC, minimum inhibitory concentration; AgNPs, silver nanoparticles; CLSI, Clinical Laboratory Standards Institute.
